<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36481735</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-0208</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><Issue>6</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Neuroepidemiology</Title><ISOAbbreviation>Neuroepidemiology</ISOAbbreviation></Journal><ArticleTitle>Cardiovascular Diseases, Medications, and ALS: A Population-Based Case-Control Study.</ArticleTitle><Pagination><StartPage>423</StartPage><EndPage>432</EndPage><MedlinePgn>423-432</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000526982</ELocationID><Abstract><AbstractText Label="INTRODUCTION">We investigated the associations between antecedent all-cause CVD diagnoses, cause-specific CVD diagnosis, and CVD medication prescriptions with the risk of developing amyotrophic lateral sclerosis (ALS).</AbstractText><AbstractText Label="MATERIALS AND METHODS">We conducted a population-based case-control study of U.S. Medicare enrollees from 2006 to 2013. The final sample included 3,714 incident ALS cases and 18,570 controls (matched on age, sex, enrollment length, and county). Information was collected from Medicare Parts A, B, and D administrative claims data on hypertension, ischemic heart disease, heart failure, acute myocardial infarction, atrial fibrillation, prescriptions of angiotensin-converting enzyme inhibitors, angiotensin II receptors blockers, calcium channel blockers, beta blockers, and antiarrhythmics. Associations were evaluated using conditional logistic regression adjusting for age, sex, race/ethnicity, geographical location, alcohol and tobacco use, and socioeconomic status.</AbstractText><AbstractText Label="RESULTS">The odds ratio (OR) for having one or more ICD-9 codes for any cardiovascular disease diagnosis at least 24 months prior to the date of ALS diagnosis was 0.85 (95% con&#xfb01;dence interval [CI]: 0.78-0.92). Cardiovascular conditions that were inversely associated with ALS included heart failure (OR = 0.79; 95% CI 0.70-0.89), atrial fibrillation (OR = 0.81; 95% CI 0.77-0.92), and hypertension (OR = 0.91; 95% CI 0.84-0.98). Exposures to several classes of cardiovascular medications were inversely associated with ALS risk even after adjusting for confounding by indication, including ACE inhibitors (OR = 0.84, 95% CI 0.77-0.91), calcium channel blockers (OR = 0.64, 95% CI 0.59-0.70), and beta blockers (OR = 0.76, 95% CI 0.71-0.83).</AbstractText><AbstractText Label="DISCUSSION/CONCLUSION">These findings merit additional research, including animal studies and pilot clinical trials, to further evaluate and evidence the effects of ACEIs, CCBs, and BBs on the risk of developing and clinical expression of ALS.</AbstractText><CopyrightInformation>&#xa9; 2022 The Author(s). Published by S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abdel Magid</LastName><ForeName>Hoda S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Population Health, Stanford University, Stanford, California, USA, hmagid@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanford Center for Population Health Sciences, Stanford University School of Medicine, Stanford, California, USA, hmagid@stanford.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Topol</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Population Health, Stanford University, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGuire</LastName><ForeName>Valerie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Population Health, Stanford University, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hinman</LastName><ForeName>Jessica A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Population Health, Stanford University, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasarskis</LastName><ForeName>Edward J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Kentucky, Lexington, Kentucky, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Lorene M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Population Health, Stanford University, Stanford, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanford Center for Population Health Sciences, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 TS000249</GrantID><Acronym>TS</Acronym><Agency>ATSDR CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01TS000249</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Neuroepidemiology</MedlineTA><NlmUniqueID>8218700</NlmUniqueID><ISSNLinking>0251-5350</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000319">Adrenergic beta-Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="Y">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006278" MajorTopicYN="N">Medicare</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000319" MajorTopicYN="N">Adrenergic beta-Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Angiotensin-converting enzyme inhibitors</Keyword><Keyword MajorTopicYN="N">Cardiovascular disease</Keyword><Keyword MajorTopicYN="N">Hypertension</Keyword><Keyword MajorTopicYN="N">Medications</Keyword></KeywordList><CoiStatement>Dr. Lorene Nelson receives grants from the National Institutes of Health, National MS Society, and Centers for Disease Control. Dr. Nelson receives compensation for serving as a consultant to Acumen, Inc. Dr. Kasarskis receives support for clinical ALS trials from the Healey platform trial program, AB Science, Alexion, and Amylx. Dr. Kasarskis also receives support from the Crispen and Team 7 endowments for ALS research. All other authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>9</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36481735</ArticleId><ArticleId IdType="pmc">PMC9986836</ArticleId><ArticleId IdType="doi">10.1159/000526982</ArticleId><ArticleId IdType="pii">000526982</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10((5&#x2013;6)):310&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Kaye W, Raymond J, Punjani R, Larson T, Cohen J, et al. Prevalence of amyotrophic lateral sclerosis: United States, 2015. Morb Mortal Wkly. 2018;67((46)):1285&#x2013;1289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289079</ArticleId><ArticleId IdType="pubmed">30462626</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur KC, Calvo A, Price TR, Geiger JT, Chio A, Traynor BJ. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun. 2016;7((1)):12408&#x2013;12406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4987527</ArticleId><ArticleId IdType="pubmed">27510634</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Bastida J, Perestelo-P&#xe9;rez L, Mont&#xf3;n-Alvarez F, Serrano-Aguilar P, Alfonso-Sanchez JL. Social economic costs and health-related quality of life in patients with amyotrophic lateral sclerosis in Spain. Amyotroph Lateral Scler. 2009;10((4)):237&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">18821088</ArticleId></ArticleIdList></Reference><Reference><Citation>Schepelmann K, Winter Y, Spottke AE, Claus D, Grothe C, Schroder R, et al. Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurology. 2010;257((1)):15&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">19629566</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabjerg BB, Garton FC, van Rheenen W, Fang F, Henderson RD, Mortensen PB, et al. ALS in Danish Registries: heritability and links to psychiatric and cardiovascular disorders. Neurol Genet. 2020;6((2)):e398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7073454</ArticleId><ArticleId IdType="pubmed">32211514</ArticleId></ArticleIdList></Reference><Reference><Citation>Kioumourtzoglou M-A, Seals RM, Gredal O, Mittleman MA, Hansen J, Weisskopf MG. Cardiovascular disease and diagnosis of amyotrophic lateral sclerosis: a population-based study. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17((7&#x2013;8)):548&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5178102</ArticleId><ArticleId IdType="pubmed">27436717</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau C, Brunaud-Danel V, Dallongeville J, Duhamel A, Laurier-Grymonprez L, de Reuck J, et al. Modifying effect of arterial hypertension on amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012;13((2)):194&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">21913867</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Xu L, Tang L, Xia K, Tian D, Zhang G, et al. Trends in the clinical features of amyotrophic lateral sclerosis: a 14-year Chinese cohort study. Eur J Neurol. 2021;28((9)):2893&#x2013;2900.</Citation><ArticleIdList><ArticleId IdType="pubmed">34048130</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman DM, Wu J, Daugherty SE, Kuncl RW, Enewold LR, Pfeiffer RM. The risk of amyotrophic lateral sclerosis after cancer in US elderly adults: a population-based prospective study. Int J Cancer Res. 2014;135((7)):1745&#x2013;1750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4107108</ArticleId><ArticleId IdType="pubmed">24550098</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira M, Gromicho M, Henriques A, Pronto-Laborinho AC, Grosskreutz J, Kuzma-Kozakiewicz M, et al. Cardiovascular comorbidities in amyotrophic lateral sclerosis. J Neurol Sci. 2021;421:117292.</Citation><ArticleIdList><ArticleId IdType="pubmed">33423011</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, Ferri L, Fasano A, Zucchi E, Fini N, Moglia C, et al. Cardiovascular diseases may play a negative role in the prognosis of amyotrophic lateral sclerosis. Eur J Neurol. 2018;25((6)):861&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">29512869</ArticleId></ArticleIdList></Reference><Reference><Citation>Garton FC, Trabjerg BB, Wray NR, Agerbo E. Cardiovascular disease, psychiatric diagnosis and sex differences in the multistep hypothesis of amyotrophic lateral sclerosis. Eur J Neurol. 2021;28((2)):421&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">32978838</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Wotton C, Talbot K, Goldacre MJ. Cardiovascular fitness as a risk factor for amyotrophic lateral sclerosis: indirect evidence from record linkage study. J Neurol Neurosurg Psychiatry. 2012;83((4)):395&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">22072701</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;rner S, Kollewe K, Ilsemann J, Muller-Heine A, Dengler R, Krampfl K, et al. Prevalence and prognostic impact of comorbidities in amyotrophic lateral sclerosis. Eur J Neurol. 2013;20((4)):647&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">23094606</ArticleId></ArticleIdList></Reference><Reference><Citation>Moglia C, Calvo A, Canosa A, Bertuzzo D, Cugnasco P, Solero L, et al. Influence of arterial hypertension, type 2 diabetes and cardiovascular risk factors on ALS outcome: a population-based study. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18((7&#x2013;8)):590&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pubmed">28616937</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchi C, Bianchi E, Pupillo E, Poloni M, Nobili A, Fortino I, et al. Angiotensin-converting enzyme inhibitors and motor neuron disease: an unconfirmed association. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17((5&#x2013;6)):385&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">26913547</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin F-C, Tsai C-P, Kuang-Wu Lee J, Wu M-T, Tzu-Chi Lee C. Angiotensin-converting enzyme inhibitors and amyotrophic lateral sclerosis risk: a total population-based case-control study. JAMA Neurol. 2015;72((1)):40&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">25383557</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer RM, Mayer B, Kuncl RW, Check DP, Cahoon EK, Rivera DR, et al. Identifying potential targets for prevention and treatment of amyotrophic lateral sclerosis based on a screen of medicare prescription drugs. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21((3&#x2013;4)):235&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9930913</ArticleId><ArticleId IdType="pubmed">31684770</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaye WE, Sanchez M, Wu J. Feasibility of creating a National ALS Registry using administrative data in the United States. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15((5&#x2013;6)):433&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4587982</ArticleId><ArticleId IdType="pubmed">24597459</ArticleId></ArticleIdList></Reference><Reference><Citation>Wacholder S, Silverman DT, McLaughlin JK, Mandel JS. Selection of controls in case-control studies: III. Design options. Am J Epidemiol. 1992;135((9)):1042&#x2013;1050.</Citation><ArticleIdList><ArticleId IdType="pubmed">1595690</ArticleId></ArticleIdList></Reference><Reference><Citation>Algorithms, Chronic Conditions Warehouse (CCW)  Centers for Medicare and Medicaid Services (CMS) 2021.  Available from:  https://www.ccwdata.org/</Citation></Reference><Reference><Citation>Wannarong T, Ungprasert P. Diabetes mellitus is associated with a lower risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. Clin Neurol Neurosurg. 2020;199:106248.</Citation><ArticleIdList><ArticleId IdType="pubmed">33031990</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Reilly &#xc9;J, Wang H, Weisskopf MG, Fitzgerald KC, Falcone G, McCullough ML, et al. Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14((3)):205&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3615420</ArticleId><ArticleId IdType="pubmed">23134505</ArticleId></ArticleIdList></Reference><Reference><Citation>Kioumourtzoglou M-A, Rotem RS, Seals RM, Gredal O, Hansen J, Weisskopf MG. Diabetes mellitus, obesity, and diagnosis of amyotrophic lateral sclerosis: a population-based study. JAMA Neurol. 2015;72((8)):905&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4975611</ArticleId><ArticleId IdType="pubmed">26030836</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, O'Reilly &#xc9;J, Weisskopf MG, Logroscino G, McCullough ML, Thun MJ, et al. Smoking and risk of amyotrophic lateral sclerosis: a pooled analysis of 5 prospective cohorts. Arch. Neurol. 2011;68((2)):207&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319086</ArticleId><ArticleId IdType="pubmed">21320987</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldink JH, Kalmijn S, Groeneveld GJ, Titulaer MJ, Wokke JHJ, van den Berg LH. Physical activity and the association with sporadic ALS. Neurol. 2005;64((2)):241&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">15668420</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacorte E, Ferrigno L, Leoncini E, Corbo M, Boccia S, Vanacore N. Physical activity, and physical activity related to sports, leisure and occupational activity as risk factors for ALS: a systematic review. Neurosci Biobehav Rev. 2016;66:61&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">27108217</ArticleId></ArticleIdList></Reference><Reference><Citation>Armon C, Kurland LT, O'Brien PC, Mulder DW. Antecedent medical diseases in patients with amyotrophic lateral sclerosis: a population-based case-controlled study in Rochester, Minn, 1925 through 1987. Arch Neurol. 1991;48((3)):283&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">2001186</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n MA, Hern&#xe1;ndez-D&#xed;az S, Robins JM. A structural approach to selection bias. Epidemiol. 2004;15((5)):615&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pubmed">15308962</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RS, Spitzer WO, Delmore T, Sackett DL. An empirical demonstration of Berkson's bias. J Chronic Dis. 1978;31((2)):119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">659569</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkson J. Limitations of the application of fourfold table analysis to hospital data. Biometrics. 1946;2((3)):47&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">21001024</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu N, Ji H. Medications on hypertension, hyperlipidemia, diabetes, and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurol Sci. 2022;43((9)):5189&#x2013;5199.</Citation><ArticleIdList><ArticleId IdType="pubmed">35616813</ArticleId></ArticleIdList></Reference><Reference><Citation>Boill&#xe9;e S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312((5778)):1389&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerber YN, Sabourin JC, Rabano M, Vivanco MM, Perrin FE. Early functional deficit and microglial disturbances in a mouse model of amyotrophic lateral sclerosis. PLoS One. 2012;7((4)):e36000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338492</ArticleId><ArticleId IdType="pubmed">22558300</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 2011;10((3)):253&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">21349440</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur P, Muthuraman A, Kaur M. The implications of angiotensin-converting enzymes and their modulators in neurodegenerative disorders: current and future perspectives. ACS Chem Neurosci. 2015;6((4)):508&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pubmed">25680080</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengul G, Coskun S, Cakir M, Coban MK, Saruhan F, Hacimuftuoglu A. Neuroprotective effect of ACE inhibitors in glutamate-induced neurotoxicity: rat neuron culture study. Turk Neurosurg. 2011;21((3)):367&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">21845573</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravati A, Junker V, Kouklei M, Ahlemeyer B, Culmsee C, Krieglstein J. Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats. Eur J Pharmacol. 1999;373((1)):21&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408248</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki Y, Ichikawa Y, Igarash O, Ikeda K, Kinoshita M. Influence of temocapril on cultured ventral spinal cord neurons. Neurochem Res. 2003;28((5)):711&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">12716021</ArticleId></ArticleIdList></Reference><Reference><Citation>Tedeschi V, Petrozziello T, Secondo A. Calcium dyshomeostasis and lysosomal Ca2+dysfunction in amyotrophic lateral sclerosis. Cells. 2019;8((10)):1216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6829585</ArticleId><ArticleId IdType="pubmed">31597311</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Yi J, Fu R, Liu E, Siddique T, Rios E, et al. Hyperactive intracellular calcium signaling associated with localized mitochondrial defects in skeletal muscle of an animal model of amyotrophic lateral sclerosis. J Biol Chem. 2010;285((1)):705&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2804218</ArticleId><ArticleId IdType="pubmed">19889637</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin HZ, Tang DT, Weiss JH. Intrathecal infusion of a Ca2+-permeable AMPA channel blocker slows loss of both motor neurons and of the astrocyte glutamate transporter, GLT-1 in a mutant SOD1 rat model of ALS. Exp Neurol. 2007;207((2)):177&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2083564</ArticleId><ArticleId IdType="pubmed">17719032</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran LT, Gentil BJ, Sullivan KE, Durham HD. The voltage-gated calcium channel blocker lomerizine is neuroprotective in motor neurons expressing mutant SOD1, but not TDP-43. J Neurochem. 2014;130((3)):455&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">24716897</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez LR, Lape&#xf1;a-Luz&#xf3;n T, Benet&#xf3; N, Beltran-Beltran V, Pallard&#xf3; FV, Gonzalez-Cabo P, et al. Therapeutic strategies targeting mitochondrial calcium signaling: a new hope for neurological diseases? Antioxidants. 2022;11((1)):165&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8773297</ArticleId><ArticleId IdType="pubmed">35052668</ArticleId></ArticleIdList></Reference><Reference><Citation>Z&#xfc;ndorf G, Reiser G. Calcium dysregulation and homeostasis of neural calcium in the molecular mechanisms of neurodegenerative diseases provide multiple targets for neuroprotection. Antioxid Redox Signal. 2011;14((7)):1275&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3122891</ArticleId><ArticleId IdType="pubmed">20615073</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki T, Drescher C, Palus S, Musolino V, von Haehling S, Anker SD, et al. Improved muscle fiber diameter and motoneuron number by s-oxprenolol treatment in a mouse model of amyotrophic lateral sclerosis (ALS). Abstracts of the 10th International Conference on Cachexia, Sarcopenia and Muscle Wasting, Rome, Italy, 8&#x2013;10 December 2017 (Part 2) J Cachexia Sarcopenia Muscle. 2018;9((1)):200&#x2013;201.</Citation></Reference><Reference><Citation>Hern&#xe1;n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183((8)):758&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4832051</ArticleId><ArticleId IdType="pubmed">26994063</ArticleId></ArticleIdList></Reference><Reference><Citation>Caniglia EC, Rojas-Saunero LP, Hilal S, Licher S, Logan R, Stricker B, et al. Emulating a target trial of statin use and risk of dementia using cohort data. Neurology. 2020;95((10)):e1322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7538212</ArticleId><ArticleId IdType="pubmed">32753444</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>